the product recovered per perfusion run is greatly increased, generating a more efficient method for operating perfusion processes. This is further enhanced by the positive effect on cell specific productivity.

[014] A method of culturing mammalian cells expressing a heterologous protein in a perfusion cell culture is provided comprising: (a) inoculating mammalian cells expressing a heterologous protein in a serum-free culture medium; (b) culturing the mammalian cells during growth phase by perfusion with a serum-free perfusion medium; and (c) culturing the mammalian cells during production phase by perfusion with a serum-free perfusion medium comprising potassium ions at a concentration of 30 mM to 250 mM and a molar ratio of sodium to potassium ions of less than 1, wherein step (b) is optional. In one aspect, a method of culturing rodent cells expressing a heterologous protein in a perfusion cell culture is provided comprising: (a) inoculating rodent cells expressing a heterologous protein in a serum-free culture medium; (b) culturing the rodent cells during growth phase by perfusion with a serum-free perfusion medium; and (c) culturing the rodent cells during production phase by perfusion with a serum-free perfusion medium comprising potassium ions at a concentration of 30 mM to 250 mM and a molar ratio of sodium to potassium ions of less than 1, wherein the osmolarity of the serum-free perfusion medium of step (c) is in the range between 300 and 500 mOsmol/kg; and wherein step (b) is optional.

[015] A method of reducing cell bleeding in a perfusion cell culture expressing a heterologous protein in a perfusion cell culture is provided comprising: (a) inoculating mammalian cells expressing a heterologous protein in a serum-free culture medium; (b) culturing the mammalian cells during growth phase by perfusion with a serum-free perfusion medium; and (c) culturing the mammalian cells during production phase by perfusion with a serum-free perfusion medium comprising potassium ions at a concentration of 30 mM to 250 mM and a molar ratio of sodium to potassium ions of less than 1, wherein step (b) is optional. In another aspect, a method of reducing cell bleeding in a perfusion cell culture expressing a heterologous protein is provided comprising: (a) inoculating rodent cells expressing a heterologous protein in a serum-free culture medium; (b) culturing the rodent cells during growth phase by perfusion with a serum-free perfusion medium; and (c) culturing the rodent cells during production phase by perfusion with a serum-free perfusion medium comprising potassium ions at a concentration of 30 mM to 250 mM and a molar ratio of sodium to potassium ions of less than 1, wherein the osmolarity of the serum-free perfusion medium of step (c) is in the range between 300 and 500 mOsmol/kg; and wherein step (b) is optional.

[016] A method of increasing protein production in a perfusion cell culture expressing a heterologous protein is provided comprising: (a) inoculating mammalian cells expressing a heterologous protein in a serum-free culture medium; (b) culturing the mammalian cells during growth phase by perfusion with a serum-free perfusion medium; and (c) culturing the mammalian cells during production phase by perfusion with a serum-free perfusion medium comprising potassium ions at a concentration of 30 mM to 250 mM and a molar ratio of sodium to potassium ions of less than 1, wherein step (b) is optional. In another aspect, a method of increasing protein production in a perfusion cell culture expressing a heterologous protein is provided comprising: (a) inoculating rodent cells expressing a heterologous protein in a serum-free culture medium; (b) culturing the rodent cells during growth phase by perfusion with a serum-free perfusion medium; and (c) culturing the rodent cells during production phase by perfusion with a serum-free perfusion medium comprising potassium ions at a concentration of 30 mM to 250 mM and a molar ratio of sodium to potassium ions of less than 1, wherein the osmolarity of the serum-free perfusion medium of step (c) is in the range between 300 and 500 mOsmol/kg; and wherein step (b) is optional.

[017] Step (c) is started once the target cell density is reached. Thus, it may be started at a cell density of 10 x 10^6 cells/ml to about 120 x 10^6 cells/ml or even higher. Preferably step (c) is initiated at a cell density of at least 10 x 10^6 cells/ml, at least 20 x 10^6 cells/ml, at least 30 x 10^6 cells/ml, at least 40 x 10^6 cells/ml or at least 50 x 10^6 cells/ml. Most preferably step (c) is initiated at a cell density of about 30 to about 50 x 10^6 cells/ml.

[018] Step (c) of the methods of the disclosure may further comprise maintaining a cell density by cell bleeding. Using the methods of the present disclosure the cell bleeding is reduced compared to a perfusion cell culture using the same serum-free perfusion medium comprising potassium ions at a concentration of less than 30 mM and a molar ratio of sodium to potassium of more than 2 and cultured under the same conditions.

[019] In an example of the methods of the disclosure the potassium ion concentration is about 40 mM to about 200 mM, preferably about 60 mM to about 150 mM and more preferably about 80 mM to

about 100 mM. In an example the molar ratio of sodium to potassium is between about 0.9 and 0.1, between about 0.8 and 0.2, between about 0.7 and 0.2, preferably between about 0.6 and 0.3 and more preferably between about 0.5 and 0.4.

[020] According to the present disclosure the potassium ion is provided as one or more potassium salt. In an example the one or more potassium salt is selected from the group consisting of potassium bicarbonate, potassium chloride, potassium hydroxide, L-tyrosine dipotassium salt, potassium phosphate dibasic, potassium phosphate monobasic, potassium selenite, potassium pyruvic acid, potassium glutathione, potassium D-gluconate, potassium succinate and potassium ascorbate. Preferably the one or more potassium salt substitutes the corresponding sodium salt in the serum-free perfusion culture medium. More specifically the one or more potassium salt preferably substitutes the corresponding sodium salt in the serum-free perfusion medium of step b).

[021] The osmolarity of the serum-free perfusion medium should be in the range of between 300 and 1400 mOsmol/kg, preferably between 300 and 500 mOsmol/kg, more preferably between 330 and 450 mOsmol/kg and even more preferably between 360 and 390 mOsmol/kg.

[022] The mammalian cell may be a Chinese hamster ovary (CHO) cell, preferably a CHO-DG44 cell, a CHO-K1 cell, a CHO DXB11 cell, a CHO-S cell, a CHO GS deficient cell or a derivative of any of these cells.

[023] The serum-free perfusion medium may be chemically defined and/or hydrolysate free. Preferably the serum-free perfusion medium is protein-free or protein-free except for recombinant insulin and/or insulin-like growth factor, more preferably the serum-free perfusion medium is chemically defined and protein-free or protein-free except for recombinant insulin and/or insulin-like growth factor.

[024] A method of producing a therapeutic protein using the methods of the disclosure is provided. In another aspect, a method of producing a therapeutic protein is provided comprising: (a) inoculating rodent cells expressing a heterologous protein in a serum-free culture medium; (b) culturing the rodent cells during growth phase by perfusion with a serum-free perfusion medium; and (c) culturing the rodent cells during production phase by perfusion with a serum-free perfusion medium comprising potassium ions at a concentration of 30 mM to 250 mM and a molar ratio of sodium to potassium ions of less than 1, wherein the osmolarity of the serum-free perfusion medium of step (c) is in the range between 300 and 500 mOsmol/kg; and wherein step (b) is optional. The method optionally comprises a further step of purifying and formulating the therapeutic protein into a pharmaceutically acceptable formulation.

more potassium salt substitutes the corresponding sodium salt in the serum-free perfusion culture medium.

[027] The osmolarity of the serum-free perfusion medium should be in the range of between 300 and 1400 mOsmol/kg, preferably between 300 and 500 mOsmol/kg, more preferably between 330 and 450 mOsmol/kg and even more preferably between 360 and 390 mOsmol/kg.

[028] The serum-free perfusion medium may be chemically defined and/or hydrolysate free. Preferably the serum-free perfusion medium is protein-free or protein-free except for recombinant insulin and/or insulin-like growth factor, more preferably the serum-free perfusion medium is chemically defined and protein-free or protein-free except for recombinant insulin and/or insulin-like growth factor.

[029] A use of the serum-free perfusion medium of the disclosure for culturing mammalian cells in a perfusion culture during production phase or for reducing the total cell bleed volume in a perfusion culture is provided. In another aspect, a use of the serum-free perfusion medium as described herein for culturing rodent cells in a perfusion culture during production phase is provided. In another aspect, a use of the serum-free perfusion medium as described herein for reducing the total cell bleed volume in a perfusion culture of CHO cells expressing a heterologous protein is provided. In another aspect a use of the serum-free perfusion medium of the disclosure for increasing protein production in a perfusion cell culture of CHO cells expressing a heterologous protein is provided. In another aspect, a use of the serum-free perfusion medium of the disclosure for increasing cell specific protein production in a perfusion cell culture of CHO cells expressing a heterologous protein is provided.

BRIEF DESCRIPTION OF THE DRAWINGS

[030] Figure 1: Effect of cell bleed on total productivity. A CHO cell line producing monoclonal antibody mAb1 was cultured in 3L glass perfusion bioreactors at a 2L working volume utilizing two different recirculation devices as indicated: ATF#1 and ATF#2 were replicates using an ATF2 device (Repligen, Waltham, MA) and the TFF bioreactor used a centrifugal pump (Levitronix, Zurich, Switzerland). Titer was measured for the harvest (permeate) stream (recovered product) and bioreactor contents (reactor titer) daily and the total grams produced (total produced) and product lost in the bleed and the reactor at the end of cell culture (day 29) were calculate.

CLAIMS

1. A method of culturing rodent cells expressing a heterologous protein in a perfusion cell culture comprising:

(a) inoculating rodent cells expressing a heterologous protein in a serum-free culture medium;

(b) culturing the rodent cells during growth phase by perfusion with a serum-free perfusion medium; and

(c) culturing the rodent cells during production phase by perfusion with a serum-free perfusion medium comprising potassium ions at a concentration of 30 mM to 250 mM and a molar ratio of sodium to potassium ions of less than 1,

wherein the osmolarity of the serum-free perfusion medium of step (c) is in the range between 300 and 500 mOsmol/kg; and wherein step (b) is optional.

2. A method of reducing cell bleeding in a perfusion cell culture expressing a heterologous protein comprising:

(a) inoculating rodent cells expressing a heterologous protein in a serum-free culture medium;

(b) culturing the rodent cells during growth phase by perfusion with a serum-free perfusion medium; and

(c) culturing the rodent cells during production phase by perfusion with a serum-free perfusion medium comprising potassium ions at a concentration of 30 mM to 250 mM and a molar ratio of sodium to potassium ions of less than 1,

wherein the osmolarity of the serum-free perfusion medium of step (c) is in the range between 300 and 500 mOsmol/kg; and wherein step (b) is optional.

3. A method of increasing protein production in a perfusion cell culture expressing a heterologous protein comprising:

(a) inoculating rodent cells expressing a heterologous protein in a serum-free culture medium;

(b) culturing the rodent cells during growth phase by perfusion with a serum-free perfusion medium; and

(c) culturing the rodent cells during production phase by perfusion with a serum-free perfusion medium comprising potassium ions at a concentration of 30 mM to 250 mM and a molar ratio of sodium to potassium ions of less than 1,

wherein the osmolarity of the serum-free perfusion medium of step (c) is in the range between 300 and 500 mOsmol/kg; and wherein step (b) is optional.

4. The method of any one of claims 1 to 3, wherein step (c) further comprises maintaining a cell density by cell bleeding, preferably wherein cell bleeding is reduced compared to a perfusion cell culture using the same serum-free perfusion medium comprising potassium ions at a concentration of less than 30 mM and a molar ratio of sodium to potassium of more than 2 and cultured under the same conditions.

5. The method of any one of the preceding claims, wherein the potassium ion concentration is 40 mM to 200 mM, preferably 60 mM to 150 mM and more preferably 80 mM to 100 mM.

6. The method of any one of the preceding claims, wherein the molar ratio of sodium to potassium is between 0.9 and 0.1, between 0.8 and 0.2, between 0.7 and 0.2, preferably between 0.6 and 0.3 and more preferably between 0.5 and 0.4.

7. The method of any one of the preceding claims, wherein the potassium ion is provided as one or more potassium salt, preferably wherein the one or more potassium salt is selected from the group consisting of potassium bicarbonate, potassium chloride, potassium hydroxide, L-tyrosine dipotassium salt, potassium phosphate dibasic, potassium phosphate monobasic, potassium selenite, potassium pyruvic acid, potassium glutathione, potassium D-gluconate, potassium succinate and potassium ascorbate, more preferred wherein the one or more potassium salt substitutes the corresponding sodium salt in the serum-free perfusion culture medium, most preferred wherein the potassium ion is provided as one or more potassium salt and the one or more potassium salt substitutes the corresponding sodium salt in the serum-free perfusion medium of step b).

8. The method of any one of the preceding claims, wherein the rodent cell is a Chinese hamster ovary (CHO) cell, preferably a CHO-DG44 cell, a CHO-K1 cell, a CHO DXB11 cell, a CHO-S cell or a CHO GS deficient cell.

9. The method of any one of the preceding claims, wherein the heterologous protein is a therapeutic protein, preferably selected from the group consisting of an antibody, a fusion protein, a cytokine and a growth factor.

10. A method of producing a therapeutic protein comprising:

(a) inoculating rodent cells expressing a heterologous protein in a serum-free culture medium;

(b) culturing the rodent cells during growth phase by perfusion with a serum-free perfusion medium; and

(c) culturing the rodent cells during production phase by perfusion with a serum-free perfusion medium comprising potassium ions at a concentration of 30 mM to 250 mM and a molar ratio of sodium to potassium ions of less than 1,

wherein the osmolarity of the serum-free perfusion medium of step (c) is in the range between 300 and 500 mOsmol/kg; and wherein step (b) is optional.

11. A serum-free perfusion medium comprising potassium ions at a concentration of 30 mM to 250 mM and a molar ratio of sodium to potassium ions of less than 1, wherein the osmolarity of the serum-free perfusion medium is in the range between 300 and 500 mOsmol/kg.

12. Use of the serum-free perfusion medium of claim 11 for culturing rodent cells in a perfusion culture during production phase.

13. Use of the serum-free perfusion medium of claim 11 for reducing the total cell bleed volume in a perfusion culture of CHO cells expressing a heterologous protein.

14. Use of the serum-free perfusion medium of claim 11 for increasing protein production in a perfusion cell culture of CHO cells expressing a heterologous protein.

15. Use of the serum-free perfusion medium of claim 11 for increasing cell specific protein production in a perfusion cell culture of CHO cells expressing a heterologous protein.